期刊
ALLERGY
卷 67, 期 8, 页码 969-975出版社
WILEY
DOI: 10.1111/j.1398-9995.2012.02845.x
关键词
asthma; atopic dermatitis; atopic march; disease modification
资金
- Astellas
- Novartis
- Intendis
- Astellas Europe
- Almirall
- Astellas Pharma
- Johnson Johnson
- Leo Pharmaceuticals
- Reckitt Benckiser
- Stiefel (a GSK company)
The concept of disease modification has been introduced to define the therapeutic strategies aimed to break, stop, or reverse the natural course of a chronic invalidating disease. This strategy is tightly related to the biomarker-based stratification of affected patients using genetic and other biological markers. With regard to the progress in understanding the genetic background of atopic dermatitis (AD), its natural history and its pivotal role in the emergence of allergic asthma, the time is mature to foster the research field of biomarkers in AD and to consider the elaboration of disease-modifying strategies in the management of AD with the goal to stop or even reverse the atopic march.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据